Early Detection of Prostate Cancer by Liquid Biopsy
Condition: Prostate Cancer
Study Type: Interventional
Clinical Trials Identifier NCT 8-digits: NCT04556916
Sponsor: University Hospital, Montpellier
Eligibility:
- Age: minimum 40 Years maximum N/A
- Gender: Male
Inclusion Criteria:
- Patient :
- Men over 40 being suspicious of prostate cancer
- Subject with PSA ≥ 4 and designated for biopsy
- Subjects must be able to attend all scheduled visits and to comply with all trial procedures
- mpMRI done before prostate biopsy
- Subject must be covered by public health insurance
- Signed informed consent form Inclusion Criteria Subject Control Patient patient free from prostatic disease :
- Men over 40 with no suspicion of prostate cancer
- Subject with PSA < 2.5 and normal digital rectal examination
- Subject must be covered by public health insurance
- Signed informed consent form Exclusion Criteria Patient :
- Subject with histologically confirmed prostate cancer
- Subject with a verified viral infection (HIV or Hepatitis)
- Subject under Finasteride treatment
- Subject under hormonal treatment (analogs, antagonists, androgenics)
- Subject with other cancer diagnosed
- Subject unable to sign consent
- Planned longer stay outside the region that prevents compliance with the visit plan
- Subject deprived of liberty, protected adults or vulnerable persons
- Urinary infection ≤ 2 months
- Subject excluding health insurance registration
- Subject refusing to perform prostate biopsy
- Subject who are in a dependency or employment with the sponsor or the investigator
Exclusion Criteria:
- Patient :
- Subject with histologically confirmed prostate cancer
- Subject with a verified viral infection (HIV or Hepatitis)
- Subject under Finasteride treatment
- Subject under hormonal treatment (analogs, antagonists, androgenics)
- Subject with other cancer diagnosed
- Subject unable to sign consent
- Planned longer stay outside the region that prevents compliance with the visit plan
- Subject deprived of liberty, protected adults or vulnerable persons
- Urinary infection ≤ 2 months
- Subject excluding health insurance registration
- Subject refusing to perform prostate biopsy
- Subject who are in a dependency or employment with the sponsor or the investigator Exclusion Criteria Subject Control :
- Subject with histologically confirmed prostate cancer
- Subject with a verified viral infection (HIV or Hepatitis)
- Subject under Finasteride treatment
- Subject with other cancer diagnosed
- Subject unable to sign consent
- Planned longer stay outside the region that prevents compliance with the visit plan
- Subject deprived of liberty, protected adults or vulnerable persons
- Urinary infection ≤ 2 months
- Subject excluding health insurance registration
View trial on ClinicalTrials.gov